Table 4 Clinical inputs.

From: Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China

Parameter

Values

Source/assumption

OWSA

Lower

Upper

COPD through FEV1 Decline (L/year)a

0.041

41

0.033

0.049

Annual probability to discover COPD from “undetected”b

 Mild COPD

20.00%

KOL interview

16.00%

24.00%

 Moderate COPD

50.00%

KOL interview

40.00%

60.00%

 Severe/very severe COPD

90.00%

KOL interview

72.00%

100.00%

Treatment effects (mean change in through FEV1 L/month)

 LAMA + LABA

0.026

Supplementary Table 3

0.021

0.031

 LABA + ICS

0.031

Supplementary Table 3

0.025

0.037

 LABA alone

0.013

Supplementary Table 3

0.010

0.016

 LAMA alone

0.022

Supplementary Table 3

0.018

0.027

 LABA + LAMA + ICS

0.025

Supplementary Table 3

0.020

0.030

% COPD patient to develop exacerbation

 Mild COPD 

19.00%

35,36

15.20%

22.80%

 Moderate COPD

19.00%

35,36

15.20%

22.80%

 Severe/very severe COPD

26.50%

35,36

21.20%

31.80%

% of exacerbations treated in hospital

 Mild COPD

68.42%

35,36

54.74%

82.11%

 Moderate COPD

68.42%

35,36

54.74%

82.11%

 Severe/very severe COPD

66.04%

35,36

52.83%

79.25%

Mortality of severe exacerbation

1.28%

37

0.50%

10.00%

Risk of serious pneumonia

 Monthly incidence of serious pneumonia

0.20%

38

0.16%

0.25%

 Mortality of serious pneumonia

3.33%

38

2.66%

3.99%

  1. SABA short acting beta agonists, SAMA short acting muscarinic antagonists, LAMA long acting muscarinic antagonists, LABA long acting beta agonists, ICS inhaled corticosteroids, KOL key opinion leader.
  2. aThe FEV1 decline rate was transformed to L/month when used in the model. The transformed equation is: decline rate (L/month) = decline rate (L/year)/12.
  3. bThe annual detected probability was transformed to monthly probability when used in the model. The transformed equation is: monthly probability = 1−exp (ln (1-annual probability)/12).